Business
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology
SAN DIEGO, March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target. Chugai intends to explore the potential use of ENHANZE® for a Chugai drug candidate.\nUnder the terms of the agreement, Chugai will make an upfront payment of $25 million to Halozyme and is obligated to make potential future payments of up to $160 million in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive royalties on sales of commercialized medicines using the ENHANZE® technology.\n\"We are thrilled to announce our latest collaboration and license agreement for ENHANZE® and look forward to working closely with Chugai to advance this program,\" said Dr. Helen Torley, president and chief executive officer. \"Our twelfth collaboration demonstrates the continued strong interest in providing patients with the option to receive treatment through a subcutaneous injection. This new collaboration further expands the number of Wave 5 potential launch programs, which we project will extend the revenue duration of our ENHANZE® franchise.\"\nChugai represents Halozyme's twelfth global collaboration and license partner for the ENHANZE® technology. These collaborations cover more than 60 therapeutic targets and include five commercialized products to date.\nAbout ENHANZE® Technology\nHalozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE® may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.\nAbout Halozyme\nHalozyme is a biopharmaceutical company bringing disruptive solutions to signifi...